Page 1

SCIBASE INTERIM REPORT JANUARY - JUNE 2026 SCIBASE 1 Interim report January 1 - June 30 , 2026 The second quarter in figures • Net sales were TSEK 15,308 ( 8,791 ) , + 74 % , cleared for currency effects + 84 % . . The loss after tax was TSEK 28,893 ( 22,911 ) . • The loss per share was SEK 2.83 ( 6.77 ) . • The cash flow from current operations was negative in the amount of TSEK 33,095 ( 20,466 ) . • The gross margin was 52,6 % ( 66.2 % ) . • Electrode sales volume increased by 118 % and was 40,144 ( 18,398 ) units . Repeat sales of electrodes to existing customers increased by 75 % ( incl deliveries to Castle ) . The first half - year in figures • Net sales were TSEK 29,586 ( 17,648 ) , + 68 % , cleared for currency effects + 79 % . • The loss after tax was TSEK 53,383 ( 43,592 ) . • The loss per share was SEK 5.80 ( 13.69 ) . • The cash flow from current operations was negative • in the amount of TSEK 59,669 ( 46,467 ) . The gross margin was 51.0 % ( 68.4 % ) . • Electrode sales volume increased by 95 % and was 70,556 ( 36,268 ) units . Repeat sales of electrodes to existing customers increased by 74 % ( incl deliveries to Castle ) . Important events during the quarter • Overall sales increased by 74 % ( + 84 % , before currency effects ) . Sales in Germany within the skin cancer segment increased by 18 % vs Q2-25 ( increased by 18 % in local currency ) . Sales in the US skin cancer market increased by 80 % [ 88 % in local currency ) while the sales within the skin barrier segment increased by 3,231 % . ⚫ The gross margin was negatively affected in the quarter by the currency development [ negative impact of over 5 % ) , continued deliveries of products to Castle Biosciences for clinical studies , increased price on gold and continued investments to ramp up production . Cleared for currency effects and Castle deliveries , the margin was around 70 % . • SciBase collaboration with Castle has now entered the next phase as the first patient has been . . included in a new study to assess flare prediction in Atopic Dermatitis . SciBase performed a reverse split 1 : 100 . A new study was published in the peer - reviewed journal Allergy demonstrating that results from Nevisense measurements obtained shortly after birth identified children who subsequentially developed atopic dermatitis ( AD ) . A new study was presented demonstrating that Nevisense ( EIS ) can successfully detect and quantify age - related changes in the skin barrier . A study was presented showing that Nevisense can identify damage to the skin barrier from surfactants in household cleaning products . ⚫ SciBase reaches milestone with over 400,000 tests sold globally . • The 2026 AGM was held on May 19th Important events after the end of the period • SciBase submitted a 510 ( k ) premarket notification to the U.S. Food and Drug Administration ( FDA ) seeking to expand the U.S. indication for Nevisense to include the assessment of Non - Melanoma Skin Cancers ( keratinocyte skin cancers ) . SciBase announced changes in senior management . Financial overview July 1 , 2025 - THE GROUP Net sales , SEKths Gross margin , % Equity / Asset ratio , % Net indebtness , multiple Apr 1 June 30 2026 2025 Jan 1 June 30 2026 2025 June 30 , 2026 Jan 1 - Dec 31 Rolling - 12 2025 15 308 8 791 52,6 % 66,2 % 29586 51,0 % 17648 68,4 % 52 400 40461 57,5 % 67,0 % 41,4 % 61,1 % 41,4 % 61,1 % 49,7 % 12,8 % 2,13 Cash equivalents , SEK ths 37153 0,64 23 958 Cashflow from operating activities , SEKths -33 095 Earnings per share ( before and after dilution ) , SEK * -2,83 -20466 -6,77 2,13 37153 -59669 -5,80 0,64 23958 -46 467 -13,69 Shareholder's equity per share , SEK * 2,96 9,55 3,28 10,14 1,01 37 153 -97 780 -14,64 4,72 6,84 22 604 -84 579 -24,16 1,85 Average number of shares , 000 ** 10225 3383 9211 3 185 6617 3 604 Number of shares at closing of period , 000 ** 10225 3663 10225 3663 10225 4142 Share price at end of period , SEK * 32,50 38,00 32,50 38,00 32,50 29,00 Number of sold electrodes , pieces 40144 18 398 70 556 36268 120468 86 180 51 35 49 34 44 37 Average number of employees * Recalculated for in June 2026 performed reverse split , 1 : 100 . Definitions and a glossary are provided on page 21 ,